



Friday Satellite Symposia

Preceding the 64th ASH Annual Meeting and Exposition



Maximizing Our Clinical Practices in Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings



IN-PERSON + LIVE STREAMING SATELLITE SYMPOSIUM

FRIDAY, DECEMBER 9, 2022

3:00 PM - 6:00 PM CST

PROGRAM CHAIR

David J. Straus, MD

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #gotoPER.

WELCOME

Dear Colleague:

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend **Medical Crossfire®: Maximizing Our Clinical Practices in Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings**.

This program will present current and cutting-edge therapies for patients with Hodgkin lymphoma (HL). Following an overview of HL, we will discuss state-of-the-art approaches for initial therapy and for patients with relapsed/refractory disease. We will also discuss unique considerations for pediatric patients with HL. Approaches to optimize the safety of therapy will be outlined. Additionally, interactive Medical Crossfire® panels will highlight incorporation of real-world evidence into case-based discussions.

In working with PER®, we strive to make this activity, along with all PER® accredited continuing education (CE) activities, useful and impactful for health care professionals who are involved with the care of patients with Hodgkin lymphoma.

If there is anything that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of Hodgkin lymphoma. Let's work together to make this an educational experience that will make a positive difference for our patients!

We hope you enjoy your experience at this first-class PER® symposium and that you can attend another PER® accredited CE activity soon.

Regards,

David J. Straus, MD

Medical Oncologist

Memorial Sloan Kettering Cancer Center

New York, NY

Jim Palatine, RPh, MBA

President

Physicians' Education Resource®, LLC

Cranbury, NJ

jpalatine@mjhlifesciences.com

AGENDA

3:00 PM	Welcome, Introductions, and Presession Survey	David J. Straus, MD
3:05 PM	Advanced Hodgkin Lymphoma (HL): Diagnosis, Targeted and Immunotherapeutic Approaches	David J. Straus, MD
3:25 PM	Frontline Therapy in HL: Clinical Outcomes and Application to Real-World Cases	Joseph M. Connors, MD, CM
4:10 PM	Question-and-Answer Session	
4:20 PM	Evidence-Based Guidelines and Clinical Advances for the Relapsed/Refractory Settings	Pier Luigi Zinzani, MD, PhD
5:05 PM	Question-and-Answer Session	
5:15 PM	Treating the Pediatric Patient: Differences and Similarities with Adult Patients	Sharon Castellino, MD, MSc
5:45 PM	Postsession Survey	
5:50 PM	Question-and-Answer Session	David J. Straus, MD
6:00 PM	Adjourn	

Upcoming PER® Conferences			2022
Inaugural International Congress Pediatric Oncology			December 16
			2023
<i>The 1st Annual Hawaii Lung: A Multidisciplinary Case-Based Conference™</i>	Honolulu, HI		January 21
<i>20th Annual Winter Lung Conference®</i>	Hollywood, FL		February 3-5
<i>19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®</i>	Dallas, TX		February 4
<i>27th Annual International Congress on Hematologic Malignancies®</i>	Miami Beach, FL		February 23-26
<i>40th Annual Miami Breast Cancer Conference®</i>	Miami Beach, FL		March 2-5
<i>NYGU™ 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies</i>	New York, NY		March 10-11
<i>8th Annual School of Gastrointestinal Oncology®</i>	Orlando, FL		May 6
<i>7th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards</i>			May 6
<i>14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies</i>			May 13
<i>22nd Annual International Congress on the Future of Breast Cancer® East</i>	New York, NY		July 15-16
<i>24th Annual International Lung Cancer Congress®</i>	Huntington Beach, CA		July 27-29
<i>22nd Annual International Congress on the Future of Breast Cancer® West</i>	San Diego, CA		July 28-29
<i>20th Annual Meeting of the International Society of Gastrointestinal Oncology®</i>	Tempe, AZ		October 13-14
<i>21st Annual School of Breast Oncology®</i>	Atlanta, GA		November 2-4
<i>41st Annual CFS®: Innovative Cancer Therapy for Tomorrow®</i>	New York, NY		November 8-10
<i>18th Annual New York Lung Cancers Symposium®</i>	New York, NY		November 11

 Virtual Conference
  In-Person + Virtual Conference
  In-Person Conference

Target Audience

This educational activity is directed toward medical oncologists, hematologists, and other oncology health care professionals interested in the latest advances in the treatment of patients with Hodgkin lymphoma. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with Hodgkin lymphoma are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Devise strategies to personalize treatment of patients with HL based on patient-related factors, risk stratification and treatment history
- Evaluate the efficacy and safety profile for current/emerging therapies among patients with advanced HL from landmark clinical trials as well as real world data across therapy lines
- Develop strategies for proactively recognizing, monitoring, and managing adverse events associated with the use of novel therapies in the management of patients with advanced HL
- Apply recent evidence from landmark trials in advanced HL to real-world scenarios encountered in the care of patients with this malignancy

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER® website by 12 PM EST, Monday, December 12, 2022. To access these materials, please visit <https://www.gotoper.com/hl1222iss-esyl>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit

<https://www.gotoper.com/hl1222iss-eval>.

The online evaluation and request for credit will be available immediately following the program and will remain available until January 23, 2023.

Accreditation/Designation of Credit

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 3.0 *AMA PRA Category 1 Credits*™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Seagen Inc. and Takeda Pharmaceuticals U.S.A., Inc.

Thank you for attending **Medical Crossfire®: Maximizing Our Clinical Practices in Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings**

To register for upcoming accredited CE live activities
or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER® accredited CE activities.



ACTIVITY OVERVIEW

Faculty, Staff, and Planners' Disclosures

The following individual has no relevant financial relationships with ineligible companies to disclose: Joseph M. Connors, MD, CM and the staff of Physicians' Education Resource®, LLC

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Speakers' Bureau	Other
David J. Straus, MD		Bayer, DAVA Pharmaceuticals, Inc, Elsevier, Juno Pharmaceuticals Corp, Millennium Pharmaceuticals, Inc, ONCOtracker, Inc, Seagen Inc	Roche	
Sharon Castellino, MD, MSc				Seagen Inc (moderator, scientific advisory board, no honorarium received)
Pier Luigi Zinzani, MD, PhD		AstraZeneca, BeiGene, Bristol Myers Squibb, EUSA Pharma, Gilead Sciences, Inc, Incyte, Janssen, Kyowa Kirin, MSD, Novartis Pharmaceuticals Corporation, Roche, Takeda	AstraZeneca, BeiGene, Bristol Myers Squibb, EUSA Pharma, Gilead Sciences, Inc, Incyte, Janssen, Kyowa Kirin, MSD, Novartis Pharmaceuticals Corporation, Roche, Takeda	

**Information accurate at time of printing*

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Program Chair



David J. Straus, MD

Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

David J. Straus, MD, is an Attending Physician at Memorial Hospital, Member of Memorial Sloan Kettering Cancer Center, and Professor of Clinical Medicine at Cornell University Medical College.

Dr. Straus received his undergraduate degree from the University of Chicago, medical degree from the Medical College of Wisconsin (Marquette School of Medicine). He completed an internal medicine internship at Montefiore Hospital; a clinical hematology fellowship at Beth Israel Hospital and fellowships in medical oncology and clinical hematology at Memorial Hospital. Dr. Straus is board certified in internal medicine, hematology, and medical oncology.

Dr. Straus is extensively published in clinical Lymphoma and regularly participates in clinical research. He is affiliated with multiple professional associations, including the American College of Physicians, the American Society of Hematology, the American Society of Clinical Oncology, the American Association for Cancer Research, and the American Medical Association.

Faculty



Sharon Castellino, MD, MSc

Professor, Department of Pediatrics, Emory University School of Medicine
Director, Leukemia and Lymphoma Program
The Aflac Cancer and Blood Disorders Center
Children's Healthcare of Atlanta
Atlanta, GA

Dr Castellino is a professor of pediatrics at the Emory University School of Medicine, and the director of the Leukemia and Lymphoma Program at the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta, Georgia. She is the scientific chair for the Children's Oncology Group (COG) Hodgkin Lymphoma Committee and had been the study chair of several clinical trials for high-risk Hodgkin lymphoma. Her expertise is in analysis of outcomes and late effects in patients with hematologic malignancies. Her focus on survivorship has been as a member of the Children's Oncology Group Survivorship Guidelines Committee.



Joseph M. Connors, MD, CM

Emeritus Professor, University of British Columbia
BC Cancer Centre for Lymphoid Cancer
Vancouver, BC, Canada

Joseph M. Connors, MD, CM, is a clinical professor emeritus in the Department of Medicine, Division of Medical Oncology, at the University of British Columbia and past Clinical Director of the BC Cancer Centre for Lymphoid Cancer.

Dr Connors obtained his medical degree at Yale University, trained in internal medicine at the University of North Carolina in Chapel Hill, and completed his medical oncology fellowship with Dr Saul Rosenberg at the

Stanford University Medical Center. He then joined the staff and faculty at BC Cancer and the University of British Columbia and has focused his clinical activities and research efforts on lymphoid cancers and, most recently, on the application of genomic analysis to understanding and optimizing treatment for these diseases.

Dr Connors is best known for his clinical investigations into the biology and treatment of Hodgkin lymphoma, non-Hodgkin lymphoma, chronic lymphocytic leukemias, and myeloma. He previously served as a member of the executive committee of the Hematology Site Group for the NCIC Clinical Trials Group, on the scientific advisory board of the Lymphoma Foundation Canada and on the organizing committee of the International Conference on Malignant Lymphoma. He is a current member of the organizing committee of the International Symposium on Hodgkin Lymphoma.

Dr Connors has published over 500 peer-reviewed scientific articles addressing various aspects of research into lymphoid cancers. He has been awarded membership in the Order of Canada; the Terry Fox Cancer research award by the British Columbia Medical Association (in 1983 and 2018); the Bernard L. Schwartz Memorial Award from Scripps Health, San Diego, California; the Canadian Cancer Society John W. Whittick Memorial Award from the Saskatchewan Medical Association; the Karl Musshoff lifetime achievement Award from the German Hodgkin Lymphoma Study Group; the Maria Ricci Award for translational research from Queens University and the NCIC Clinical Trials Group; the Hayne-Langley Award for translational research for hematologic diseases from Dalhousie University; the 2013 Dr Don Rix Award for Lifetime Achievement from Life Sciences BC; the John Ulmann Award at the International Conference on Malignant Lymphoma; and a Canadian Medical Association Lifetime Achievement Award. He has been recognized as a Clarivate Web of Science Highly Cited Researcher every year since the list was initiated in 2014.



Pier Luigi Zinzani, MD, PhD

Professor of Hematology

Institute of Hematology and Medical Oncology

University of Bologna

Bologna, Italy

Dr Pier Luigi Zinzani graduated in medicine and surgery, with honors from the University of Bologna, Italy, in 1984. He obtained a speciality in hematology, with honors at the University of Bologna in 1987. Dr Zinzani was awarded a postdoctoral fellowship in medical oncology by the Roger Williams Cancer Center of Providence, Rhode Island, in 1989. He has been chief of the clinical and translational program of the Lymphoma Unit at the Institute of Hematology and Medical Oncology since 1990. He is a member of the Italian Society of Hematology, the Italian Society of Experimental Hematology, the American Society of Hematology, and the American Society of Clinical Oncology.


Dr Zinzani is the Associate Professor at the Institute of Hematology and Medical Oncology, University of Bologna, and has been a full professor of Hematology at the University of Bologna since 2018. He has served as the principal investigator of more than 220 clinical trials (including phase 1 and 2 studies followed by expansion cohorts) in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, and chronic lymphocytic leukemia, including national and international multicenter studies. His current research interests include clinical trial methodology, prognostic factors in NHL, Hodgkin disease, chronic lymphocytic leukemia, new drugs development, and hairy cell leukemia.

Did you miss one of our sessions?


Check out the On-Demand Video Updates
from the Annual Hematology Meeting

—*Rapid Archive from*→ **NEW ORLEANS**


Archives will be available on December 10th




**Optimized use of MRD in
Hematologic Malignancies**




State-of-the-Art CMV Care




**Emerging Treatments for
Anemia in CKD**



**Holistic Approaches in
Sickle Cell Disease Treatment**




**Diagnosis and Treatment of
Hemolytic Anemias**




**Optimized Treatments for
ALL in Adolescents and Adults**




**Multidisciplinary Management
of BPDCN**




**Maximizing Clinical Practice
for Hodgkin Lymphoma**



**State-of-the-Art Care for
MF and PV**




**Exploring Gene Therapy in
Hemophilia B**



**Diagnosing Uncommon
Hematologic Disorders**



**Novel Therapies to Prevent
and Treat GvHD**



**Novel Treatments for Indolent
and Aggressive B-Cell Lymphomas**



**Treating Transfusion-Related
Iron Overload**



Scan the QR code below
or visit gotoper.com/ASH22
to view the symposia archive.

 **PER**[®]
Physicians'
Education
Resource, LLC
gotoper.com